Loading...
•
Mar 31, 2021
ORIC Pharmaceuticals Q1 2021 Earnings Report
Reported financial results and operational updates for the quarter ended March 31, 2021.
Key Takeaways
ORIC Pharmaceuticals reported its first quarter 2021 financial results, highlighting the advancement of its oncology pipeline with upcoming data readouts and IND/CTA filings. The company's cash reserves are expected to fund operations into the second half of 2023.
Lead program ORIC-101 is on track for two initial Phase 1b data readouts in 2021.
Three IND/CTA filings for ORIC-533, -944, and -114 are expected in 2021.
Two abstracts highlighting preliminary results from the Phase 1b study of ORIC-101 in combination with nab-paclitaxel have been accepted for poster presentations during the 2021 ASCO Annual Meeting.
ORIC presented posters on four programs at the 2021 American Association for Cancer Research (AACR) virtual annual meeting.
Forward Guidance
ORIC anticipates several milestones in 2021, including data reports from ORIC-101 trials and IND/CTA filings for ORIC-533, ORIC-944, and ORIC-114.
Positive Outlook
- ORIC-101: Report interim safety, efficacy, and translational data from ongoing combination trial with nab-paclitaxel at ASCO
- ORIC-101: Report interim safety, efficacy, and translational data from ongoing combination trial with enzalutamide in the second half of 2021
- ORIC-533: File an IND in the second quarter of 2021
- ORIC-944: File an IND in the second half of 2021
- ORIC-114: File a CTA in the second half of 2021
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...